Transactions With Officers and Directors. Except as set forth in the SEC Documents, none of the officers or directors of the Company has entered into any transaction with the Company or any Subsidiary that would be required to be disclosed pursuant to Item 404(a) or (c) of Regulation S-K of the SEC.
Transactions With Officers and Directors. Except pursuant to agreements or arrangements in effect on the date of this Agreement and set forth on Company Disclosure Schedule 5.01(f), pay, loan, or advance any amount to, or sell, transfer or lease any properties or assets (real, personal or mixed, tangible or intangible) to, or enter into any agreement or arrangement with, any of its officers or directors or any of their immediate family members or any Affiliates or associates (as such terms are defined under the Exchange Act) of any of its officers or directors other than compensation or business expense reimbursement in the ordinary course of business consistent with past practice.
Transactions With Officers and Directors. Except as otherwise disclosed in DME's financial statements dated December 31, 1998 and delivered to Pride Automotive Group, there have been, and through the date of Closing there will be (1) no bonuses or unusual compensation to any of the officers or directors of DME; (2) no loans, leases or contracts made to or with any of the officers or directors of DME; (3) no dividends or other distributions declared or paid by DME; and (4) no purchases by DME of any of its capital shares.
Transactions With Officers and Directors. None of the officers or directors of WinWin has entered into any transaction with WinWin or any Subsidiary that would be required to be disclosed pursuant to Item 404(a), (b) or (c) of Regulation S-K of the SEC.
Transactions With Officers and Directors. Except as set forth in the Memorandum, none of the officers or directors of the Company is presently a party to any transaction with the Company (other than for services as officers or directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer or director, or to the knowledge of the Company, any entity in which any officer or director has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $60,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for other employee benefits, including stock option agreements under any stock option plan of the Company.
Transactions With Officers and Directors. All transactions by and between the Company and any Subsidiary, on the one hand, and any officer or director of the Company or Subsidiary, on the other hand, shall be conducted on an arm’s-length basis, shall be on terms and conditions no less favorable to the Company or the Subsidiary than could be obtained from nonrelated persons and such transactions shall be approved in advance by a majority of the disinterested members of the Board; provided, however, that the foregoing approval requirement shall not apply to:
Transactions With Officers and Directors. Except as otherwise disclosed in B.A. Network's financial statements dated December 31, 1999 and delivered to ACEI, there have been, and through the date of Closing there will be (1) no bonuses or unusual compensation to any of the officers or directors of B.A. Network; (2) no loans, leases or contracts made to or with any of the officers or directors of B.A. Network; (3) no dividends or other distributions declared or paid by B.A. Network; and (4) no purchases by B.A. Network of any of its capital shares.
Transactions With Officers and Directors. Except as set forth in the SEC Reports or otherwise disclosed pursuant hereto, there are no loans, leases or other contracts outstanding between Immuno and any officer or director of Immuno or any person related to any officer or director of Immuno.
Transactions With Officers and Directors. None of the officers or directors of the Company has entered into any transaction with the Company or the Subsidiary that would be required to be disclosed pursuant to Item 404(a), (b) or (c) of Regulation S-K of the SEC. General Solicitation. Neither the Company nor any other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offers or sales of the Purchased Securities.
Transactions With Officers and Directors. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary, and, to the actual knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors or as a Purchaser under this Agreement), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or form, or otherwise requiring payments to or from any officer, director or such employee or, to the actual knowledge of the Company, any entity in which any officer, director, or any employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than (i) for payment of salary or consulting fees (on arm’s length terms) for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company or a Subsidiary and (iii) for other employee benefits, including stock option agreements under any stock option plan of the Company.
